Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Non Operating Income: 2019-2025

Historic Non Operating Income for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $2.2 million.

  • C4 Therapeutics' Non Operating Income fell 37.23% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 23.21%. This contributed to the annual value of $14.4 million for FY2024, which is 84.56% up from last year.
  • Per C4 Therapeutics' latest filing, its Non Operating Income stood at $2.2 million for Q3 2025, which was down 9.47% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Non Operating Income peaked at $3.9 million during Q1 2024, and registered a low of -$464,000 during Q2 2021.
  • For the 3-year period, C4 Therapeutics' Non Operating Income averaged around $2.7 million, with its median value being $2.8 million (2025).
  • In the last 5 years, C4 Therapeutics' Non Operating Income plummeted by 354.90% in 2021 and then soared by 5,978.57% in 2023.
  • C4 Therapeutics' Non Operating Income (Quarterly) stood at -$403,000 in 2021, then surged by 374.94% to $1.1 million in 2022, then spiked by 166.25% to $3.0 million in 2023, then increased by 10.75% to $3.3 million in 2024, then slumped by 37.23% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.5 million for Q2 2025, and $2.8 million during Q1 2025.